NASDAQ · XLO
Xilio Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for XLO: Nov 12, 2026
Xilio Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.05. The reported EPS for the same quarter last year was $-0.42.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.05 | $-1.05 | $-1.05 | 1 |
| Dec 2026 | $-1.10 | $-1.10 | $-1.10 | 1 |
| Mar 2027 | $-1.08 | $-1.08 | $-1.08 | 1 |
| Jun 2027 | $0.10 | $0.10 | $0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Sep 28, 10:15 AM EDTXilio Names Yariv Houvras Chief Medical Officer(RTTNews) – Xilio Therapeutics, Inc. (XLO), Monday announced the appointment of Yariv Houvras as Chief Medical Officer.
- RTTNews · Aug 12, 2:20 PM EDTXilio Advances XTX501; FDA Clears IND For Phase 1/2 Trial(RTTNews) – Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company developing masked immuno-oncology therapies, reported second-quarter 2026 financial results and business updates, highlighting FDA clearance of the IND for XTX501 and continued advancement of its m
- Zacks · May 18, 12:00 PM EDTCancer Stocks That Are Advancing the Future of Oncology CareOncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
- Zacks · May 12, 8:40 AM EDTXilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue EstimatesXilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 12, 8:20 AM EDTOpus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue EstimatesOpus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 11, 6:05 PM EDTOculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue EstimatesOculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 1, 12:00 PM EDTXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Fintel · Mar 27, 9:47 AM EDTXilio Therapeutics (XLO) Price Target Increased by 1,300.00% to 28.56The average one-year price target for Xilio Therapeutics (NasdaqCM:XLO) has been revised to $28.56 / share. This is an increase of 1,300.00% from the prior estimate of $2.04 dated February 21, 2026. The price target is an average of many targets provided by an
- Zacks · Mar 26, 9:18 AM EDTCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketOncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
- Zacks · Nov 13, 8:45 AM ESTXilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue EstimatesXilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Nov 12, 8:25 AM ESTBioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue EstimatesBioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Sep 29, 1:07 AM EDTFriday's Biotech Bounce: Clinical Momentum Fuels Late-Day Gains(RTTNews) – Several small- and mid-cap biotech and medical technology stocks saw notable after-hours price action on Friday, September 26, following a mix of clinical updates, investor presentations, and strategic announcements.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Xilio Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.